DAWN Company Profile and Key Details

DAWN has shown sold momentum, gaining 6.88% over the past week and 68.19% over the past quarter, though year-to-date performance is up 29.94%. Short-term trend indicators are bearishly aligned (SMA20 -6.13%, SMA50 0.61%, SMA200 31.76%). The stock’s 14-day RSI is 44.94 (neutral), while the ATR of 0.78 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -19.32% below its high and over 89.0% above its low. Average 10-day trading volume of 2.04 million shares is below the 3-month average of 2.47 million, indicating normal recent market interest.

Day One Biopharmaceuticals, Inc. has 102.43 million shares outstanding. The public float is 78.72 million shares, elevated short interest at 16.30% of float. This equals 11.28 million shares. The short ratio is 5.87 days. Institutional investors hold 103.15% of the float. Insiders own 16.94%. Canaan XI L.P. holds 8.46 million shares, Blackman Samuel C. has 1.03 million shares and AI Day1 LLC has 827.59 thousand shares. Over the past six months, insider transactions show net selling. They sold 64.46 thousand shares across 9 transactions.

Day One Biopharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $26.35. This means the shares are trading below this model’s fair value.

Day One Biopharmaceuticals, Inc. generated EPS of -$1.04 over the past year. Five-year average earnings growth is -9.72%. The latest quarter delivered EPS of -$0.19. The next quarter is forecast at -$0.28. Next year's EPS is expected at -$0.12. Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 9 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $36.00 to $16.00. The high target offers 238.03% upside. The low target suggests 50.23% downside. The mean target is $26.08. This offers 144.88% upside. Day One Biopharmaceuticals, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 04, 2025, missed forecasts by -31.75%. The prior quarter beat by -17.14%. Over the last six quarters, Apple has recorded several small beats. These include -92.54% in July 30, 2024.

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) closed at $10.65 USD, losing -$0.28 (-2.56%) from the previous close of $10.93. The stock is currently mid-range between its 52-week high and low $5.63 and $13.20. With a market capitalization of about $1.09 billion, Day One Biopharmaceuticals, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~-1.26). Key stats such as the average daily volume over the past year has been around 2.56 million shares, in line with its 52-week average. Headquartered in Brisbane, CA, Day One Biopharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jeremy Bender, the company employs approximately 181 people and listed since May 27, 2021. Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers.

Our AI price prediction model suggests that Day One Biopharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.94%, with price expected at $10.75 by March 12, 2026, within a range of $10.11 to $11.36 3-Month Outlook: Projected fall of -7.79%, reaching $9.82 by May 27, 2026, with a range of $9.51 to $10.11. 1-Year Outlook: Projected gain of 189.95%, with price at $30.88 by February 26, 2027, within a range of $24.04 to $40.56.

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) shares are up 29.94% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Day One Biopharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -10.34. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $34.15, suggesting 220.66% upside. Our AI forecast model points to short-term strength (0.94% over two weeks), a medium-term fall (-7.79% over three months), and a longer-term gain (189.95% over one year), with expected trading ranges indicating moderate volatility.

Day One Biopharmaceuticals, Inc. trades at a P/E ratio of -10.34, slightly below the S&P 500 average, with a price-to-sales ratio of 6.96 and a price-to-book ratio of 2.51 suggesting the stock is closer to book value. The P/FCF stands at -10.24, also below market averages.